Dr. Judah D. Friedman, MD

Dr. Friedman practices at Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida.

Dr. Friedman's NPI, 1134241284, was assigned on April 6, 2007. Dr. Friedman graduated from Cleveland Medical College, Homeopathic in 2001. Dr. Friedman holds Florida license ME156953.

Dr. Friedman's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West, at 1708 Cape Coral W Pkwy, Cape Coral, FL 33914 in Lee County. The practice phone is (239) 541-4633.

Dr. Friedman's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida. Dr. Friedman is also affiliated with Cleveland Clinic Martin North Hospital. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Friedman to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Friedman practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Friedman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Friedman is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Friedman's licenses on file in 3 states: Florida, Ohio and Michigan.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and neutropenia among the conditions Dr. Friedman treats.

CMS data shows 101,476 Medicare services from Dr. Friedman across 51 procedure codes in 2024, for 810 Medicare patients. Medicare paid $2,170,500 for them.

CMS counts 810 Medicare patients who saw Dr. Friedman in 2024. The largest group is 75 to 84, with 316 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Friedman's median patient age at 69, with 60% women.

In 2024, Dr. Friedman wrote 1,973 Medicare Part D claims for 298 patients. 82% of them were for generic drugs. CMS names the drug for 1,508 of them, across 54 drugs with 11 or more claims each, at $2,154,248 in total drug cost. In 2023, CMS named 610 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Friedman for performance year 2024, reported as part of a group. Dr. Friedman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Friedman as offering telehealth.

Dmand AI links 8 papers to Dr. Friedman, published from 2008 to 2024. The most frequent topics are Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols and Docetaxel. Dr. Friedman's most frequent co-authors are Rangaswamy Akhanda Chintapatla, MD, Michelle A. Fanale, MD and Tatyana A. Feldman, MD.

Dmand AI links Dr. Friedman to 1 clinical trial. Conditions studied include Hodgkin Disease and Lymphoma.

CMS Open Payments shows 1,450 general payments to Dr. Friedman from 82 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 80% of the total. GlaxoSmithKline, LLC. paid the most, $93,458.

Dr. Friedman graduated from Cleveland Medical College, Homeopathic in 2001.

Dr. Friedman is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.